Background: Despite several clinical trials and advances in understanding the genetic basis
of biliary tract cancer (BTC), the addition of epidermal growth factor receptor (EGFR) …

4520 Background: There is no standard regimen for palliative chemotherapy of advanced
biliary cancers. The GEMOX regimen is an option (BJC 2008). EGFR over-expression has …

Background Combination chemotherapy has shown benefit in the treatment of biliary cancer
and further improvements might be achieved by the addition of a biological agent. We report …

Background Chemotherapy is a standard regimen for advanced or relapsed biliary tract
cancer (BTC) with a 5-year overall survival (OS) rate of approximately 5% and a median OS …

Addition of cetuximab showed trend, but not significantly, to improve the therapeutic effects
of gemcitabine and oxaliplatin combination for advanced biliary tract cancer in current …

Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the
standard of care for advanced biliary cancers. We investigated the addition of cetuximab to …

Background Immune checkpoint inhibitors monotherapy has been studied in patients with
advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and …

PURPOSE Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 4%-
16% of biliary tract cancers (BTCs). We aimed to evaluate the clinical activity of gemcitabine …

Biliary tract cancer, carcinoma of the extrahepatic bile ducts, carcinoma of the gall bladder,
ampullary carcinoma and intrahepatic cholangiocarcinoma are often identified at an …

Background Patients with biliary tract cancer have a poor prognosis, and, until recently, no
standard palliative chemotherapy has been defined. We aimed to investigate the efficacy …